GENINUS Inc. (KOSDAQ:389030)

Market Cap	135.07B
Revenue (ttm)	8.81B
Net Income (ttm)	-12.80B
Shares Out	33.35M
EPS (ttm)	-383.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,388,479
Average Volume	1,805,044
Open	3,905.00
Previous Close	3,900.00
Day's Range	3,730.00 - 4,260.00
52-Week Range	1,080.00 - 4,260.00
Beta	1.20
RSI	76.65
Earnings Date	Mar 17, 2026

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis. The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; a...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 389030

Financial Performance

In 2024, GENINUS's revenue was 6.46 billion, a decrease of -7.35% compared to the previous year's 6.97 billion. Losses were -12.27 billion, 26.7% more than in 2023.